SCANPHARM A/S

Legal ownership resolution (ejerforholdenes opløsning)

Ends at a personThe chain of majority owners ends at a person, through 1 company; legal owners in the CVR owner register only. Dandex estimate, rule v3, computed 14 Nov 2026.

Control tenure (ejerskabsperiode)

Pro: Control tenure (ejerskabsperiode) is in the Pro plan, see pricingHow long the current ultimate controller has held control, from the CVR owner register.

Group position (koncernforhold)

Has a parent, and no majority holding in a Danish companyControlled by a company in CVR; it holds 50% or more of no Danish company. Dandex estimate, rule v2, computed 14 Nov 2026.

Signing authority, structured (tegningsregel, struktureret)

Two people must act togetherThe registered signing rule needs at least two people acting together. Dandex estimate, rule v2, computed 14 Nov 2026.

EU SME size class (SMV-kategori)

Small enterprise38.6 full-time equivalents in the CVR registry, not the report, averaged over 12 of the year's 12 months, balance sheet EUR 5.3M in the 2025 report, and the same class the year before; its group's figures are not counted and could raise the class. Dandex estimate, rule v2, computed 14 Nov 2026.

Long-run headcount growth (beskæftigelsesudvikling siden 1998)

StableEmployees -0.4% a year over 10 years to Aug 2026, from 43.5 to 41.8 on average; the peak was 69 in 1998. Dandex estimate, rule v1, computed 14 Nov 2026.

Demand cyclicality (konjunkturfølsomhed)

Pro: Demand cyclicality (konjunkturfølsomhed) is in the Pro plan, see pricingHow demand for its products moves with the economy, from its industry.

Registry and report headcount compared (ansatte i register og regnskab)

Pro: Registry and report headcount compared (ansatte i register og regnskab) is in the Pro plan, see pricingThe report's average employees beside the registry's staff over the same year.

Auditor's report (revisorpåtegning)

AuditTagged in the report (cmn:TypeOfAuditorAssistance). Dandex estimate, rules and decision model v1, computed 12 Nov 2026, from the annual report for the year ending 31 Dec 2025.

Auditor's report findings (revisorpåtegning)

Pro: Auditor's report findings (revisorpåtegning) is in the Pro plan, see pricingThe auditor's findings: conclusion, going concern, emphasis, other matters, breaches.

Business model (forretningsmodel)

Manufacturer

• "Selskabets væsentligste aktiviteter består i at udvikle, producere, pakke og analysere lægemidler, kosttilskud ogkemisk/tekniske produkter." (activity text)

Decision model, probability 0.99. Dandex estimate, rules and decision model v1, computed 13 Nov 2026, from the annual report for the year ending 31 Dec 2025.

Revenue model (indtægtsmodel)

Pro: Revenue model (indtægtsmodel) is in the Pro plan, see pricingThe kinds of revenue the accounting policies name, and the main one.

Decided by Dandex with fixed rules from CVR and the filed annual reports, and for the auditor's report, the business model and the revenue model a calibrated decision model reading the report's text and the purpose clause, not registered by the company. Each label links to its definition.

DKK thousands. Annual reports via XBRL. Employees are the annual report's average and may cover a group.

Credit rating (kreditvurdering)

Pro: Credit rating (kreditvurdering) is in the Pro plan, see pricingA score from 0 to 100 with a grade from A to F, from the latest annual reports.

Capital loss (kapitaltab)

Pro: Capital loss (kapitaltab) is in the Pro plan, see pricingNegative equity, or equity below half the share capital, in the latest report.

Filing deadline and punctuality (indsendelsesfrist)

Pro: Filing deadline and punctuality (indsendelsesfrist) is in the Pro plan, see pricingThe next annual report deadline.

No changes since Dandex began following this company. For announcements from before then, see Registrations.

Pro for this company

The rows marked Pro on this page hold values in the Pro plan. For SCANPHARM A/S, that is:

Credit and debt

Net interest-bearing debt, gearing, NIBD / EBITDA, interest coverage and adjusted equity ratio, for 2021 to 2025.Credit rating, capital loss and filing deadline and punctuality.

Returns and cash flow

EBITDA / gross profit, ROIC, capex % of sales and FCFF / EBITDA, for 2021 to 2025.

Advanced estimates

Control tenure, demand cyclicality, registry and report headcount compared, auditor's report findings and revenue model.

Signals and monitoring

Signals on this company, as Dandex raises them.

See the Pro plan

Have Pro? Sign in to see the values on this page.

Signing rule (tegningsregel)

Selskabet tegnes af bestyrelsens formand og en direktør i forening eller af den samlede bestyrelse.since 30 Jan 2018

Purpose (formål)

Selskabets formål er at drive handel og produktionsince 19 Dec 2011

Audit opted out (revision fravalgt)

Nosince 1 Jul 1992

Articles of association last changed (seneste vedtægtsdato)

30 Jan 2018

From CVR, read 14 Nov 2026. Text such as the signing rule and purpose is shown as registered.

Name changes

3 in all, none in the last 5 years; latest 10 Nov 1995

Address changes

None recordedAt the current address for 34.4 years

Status changes

None recorded

Auditor changes

None recorded

From CVR, read 14 Nov 2026. A change is counted each time the registry records a new value, so a corrected address or an audit firm under a new entity counts too.

18 registrations, newest first. As published by Erhvervsstyrelsen, in Danish, with people's street addresses cut to postcode and city.

1. 27 Feb 2026
   People change

   Bestyrelse:

   Fratrådte:

   Ole Bjørn Jensen, den 25.02.2026.

   Tiltrådte:

   Andreas Bjørn Jensen, den 25.02.2026.

2. 7 Jan 2022
   People change

   Bestyrelse:

   Fratrådte:

   Holger Carsten Hansen, (formand), den 06.01.2022.

   Tiltrådte:

   Janus Doré Pagh, (formand), den 06.01.2022.

3. 28 Feb 2019
   People change

   Direktion:

   Fratrådte:

   Rolf Eckersberg, den 28.02.2019.

   Tiltrådte:

   Andreas Bjørn Jensen, (adm. dir), den 28.02.2019.

4. 30 Jan 2018
   People change

   Vedtægter ændret: 30.01.2018

   Direktion:

   Fratrådte:

   Ole Bjørn Jensen, den 30.01.2018.

   Tiltrådte:

   Rolf Eckersberg, den 30.01.2018.

   Selskabet tegnes af bestyrelsens formand og en direktør i forening eller af den samlede bestyrelse..

5. 20 Dec 2011
   OtherCapital change

   Vedtægter ændret:

   19.12.2011.

   Kapitalforhøjelse:

   kr. 1.000.000,00 indbetalt ved konvertering af gæld, kurs 450,00.

   Kapitalen udgør herefter kr. 3.000.000,00.

6. 18 Oct 2010
   People changeOther

   Bestyrelse:

   Udtrådt af bestyrelsen:

   Jens Terkel Lund-Nielsen, den 14.10.2010.

   Indtrådt i bestyrelsen:

   Group Finance Director Holger Carsten Hansen (formand), den 14.10.2010.

7. 7 Jun 2007
   OtherAudit change

   Revision:

   Udtrådt af revisionen:

   CVR-NR. 30529715 REVISIONSFIRMAET A. ROLF LARSEN, STATSAUTORISEREDE REVISORER A/S, den 05.06.2007.

   Indtrådt i revisionen:

   Statsaut. revisor Bent Lind Kofoed, 1304 København K, den 05.06.2007.

8. 1 Jan 2007
   Address change

   Ved kommunalreformen den 1. januar 2007 er hjemstedskommunen ændret.

9. 5 Dec 2002
   Status change

   Vedtægter ændret:

   06.09.2002.

   Nye binavne:

   FERRATON FARMACEUTISK FABRIK A/S (SCANPHARM A/S), CAREPACK A/S (SCANPHARM A/S), CAREPACK PHARMACEUTICAL PRODUKTION A/S (SCANPHARM A/S).

   Selskabet fusioneret med CVR-NR. 18426692 FERRATON FARMACEUTISK FABRIK A/S, CVR-NR. 20285702 CAREPACK ApS, der samtidig er opløst.

10. 27 Jun 2002
    Status change

    Erhvervs- og Selskabsstyrelsen har modtaget

    fusionsplan i henhold til aktieselskabslovens § 134 a og

    anpartsselskabslovens § 65 for fusion mellem

    CVR-NR. 16279099 SCANPHARM A/S. der tillige driver virksomhed under navnene SCANZYM A/S (SCANPHARM A/S), SCANDRUG A/S (SCANPHARM A/S), PHARMANOVA A/S (SCANPHARM A/S).

    CVR-NR. 20285702 CAREPACK ApS. der tillige driver virksomhed under navnet CAREPACK PHARMACEUTICAL PRODUCTION ApS (CAREPACK ApS).

    CVR-NR. 18426692 FERRATON FARMACEUTISK FABRIK A/S.

    Show the full announcement

    Endvidere er modtaget erklæring fra

    vurderingsmændene i henhold til aktieselskabslovens §

    134 c, stk. 4 og anpartsselskabslovens § 65.